1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Ms E Walmsley
|
|||
b)
|
Position/status
|
Chief Executive Officer
|
|||
c)
|
Initial
notification/ amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GlaxoSmithKline plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward
Plan
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£14.4732
|
8 (partnership shares)
|
|
||
|
£14.4732
|
8 (matching shares)
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
|
|||
Aggregated
volume
Price
|
16 Ordinary Shares
£14.4732
|
||||
e)
|
Date
of the transaction
|
2021-08-10
|
|||
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Mr R Connor
|
|||
b)
|
Position/status
|
President, Vaccines & Global Health
|
|||
c)
|
Initial
notification/ amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GlaxoSmithKline plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward
Plan
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£14.4732
|
8 (partnership shares)
|
|
||
|
£14.4732
|
8 (matching shares)
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
|
|||
Aggregated
volume
Price
|
16 Ordinary Shares
£14.4732
|
||||
e)
|
Date
of the transaction
|
2021-08-10
|
|||
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Ms D Conrad
|
|||
b)
|
Position/status
|
SVP, Human Resources
|
|||
c)
|
Initial
notification/ amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GlaxoSmithKline plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward
Plan
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£14.4732
|
8 (partnership shares)
|
|
||
|
£14.4732
|
8 (matching shares)
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
|
|||
Aggregated
volume
Price
|
16 Ordinary Shares
£14.4732
|
||||
e)
|
Date
of the transaction
|
2021-08-10
|
|||
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Mr J Ford
|
|||
b)
|
Position/status
|
SVP and General Counsel
|
|||
c)
|
Initial
notification/ amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GlaxoSmithKline plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward
Plan
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£14.4732
|
8 (partnership shares)
|
|
||
|
£14.4732
|
8 (matching shares)
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
|
|||
Aggregated
volume
Price
|
16 Ordinary Shares
£14.4732
|
||||
e)
|
Date
of the transaction
|
2021-08-10
|
|||
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Ms S Jackson
|
|||
b)
|
Position/status
|
SVP, Global Communications and CEO Office
|
|||
c)
|
Initial
notification/ amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GlaxoSmithKline plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward
Plan
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£14.4732
|
8 (partnership shares)
|
|
||
|
£14.4732
|
8 (matching shares)
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
|
|||
Aggregated
volume
Price
|
16 Ordinary Shares
£14.4732
|
||||
e)
|
Date
of the transaction
|
2021-08-10
|
|||
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Mr D Jackson
|
|||
b)
|
Position/status
|
PCA of Ms S Jackson (SVP, Global Communications and CEO
Office)
|
|||
c)
|
Initial
notification/ amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GlaxoSmithKline plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward
Plan
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£14.4732
|
9 (partnership shares)
|
|
||
|
£14.4732
|
9 (matching shares)
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
|
|||
Aggregated
volume
Price
|
18 Ordinary Shares
£14.4732
|
||||
e)
|
Date
of the transaction
|
2021-08-10
|
|||
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Mr D Redfern
|
|||
b)
|
Position/status
|
Chief Strategy Officer
|
|||
c)
|
Initial
notification/ amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GlaxoSmithKline plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward
Plan
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£14.4732
|
8 (partnership shares)
|
|
||
|
£14.4732
|
8 (matching shares)
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
|
|||
Aggregated
volume
Price
|
16 Ordinary Shares
£14.4732
|
||||
e)
|
Date
of the transaction
|
2021-08-10
|
|||
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Mr R Simard
|
|||
b)
|
Position/status
|
President, Pharmaceuticals Supply Chain
|
|||
c)
|
Initial
notification/ amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GlaxoSmithKline plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward
Plan
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£14.4732
|
9 (partnership shares)
|
|
||
|
£14.4732
|
9 (matching shares)
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
|
|||
Aggregated
volume
Price
|
18 Ordinary Shares
£14.4732
|
||||
e)
|
Date
of the transaction
|
2021-08-10
|
|||
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Mr P Thomson
|
|||
b)
|
Position/status
|
President, Global Affairs
|
|||
c)
|
Initial
notification/ amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GlaxoSmithKline plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward
Plan
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£14.4732
|
8 (partnership shares)
|
|
||
|
£14.4732
|
8 (matching shares)
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
|
|||
Aggregated
volume
Price
|
16 Ordinary Shares
£14.4732
|
||||
e)
|
Date
of the transaction
|
2021-08-10
|
|||
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Ms D Waterhouse
|
|||
b)
|
Position/status
|
Chief Executive Officer of ViiV Healthcare
|
|||
c)
|
Initial
notification/ amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GlaxoSmithKline plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward
Plan
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£14.4732
|
9 (partnership shares)
|
|
||
|
£14.4732
|
9 (matching shares)
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
|
|||
Aggregated
volume
Price
|
18 Ordinary Shares
£14.4732
|
||||
e)
|
Date
of the transaction
|
2021-08-10
|
|||
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Ms V Whyte
|
|||
b)
|
Position/status
|
Company Secretary
|
|||
c)
|
Initial
notification/ amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GlaxoSmithKline plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward
Plan
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£14.4732
|
8 (partnership shares)
|
|
||
|
£14.4732
|
8 (matching shares)
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
|
|||
Aggregated
volume
Price
|
16 Ordinary Shares
£14.4732
|
||||
e)
|
Date
of the transaction
|
2021-08-10
|
|||
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
GlaxoSmithKline plc
|
|
(Registrant)
|
|
|
Date: August
11, 2021
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GlaxoSmithKline plc
|